Swiss-based drug manufacturer Novartis (NYS: NVS) announced today that it has received another green light from the European Commission for its tumor drug Votubia. The tablets can now be used to treat some adults with non-cancerous kidney tumors associated with tuberous sclerosis complex (TSC).
According to the company, this is the first drug approved in Europe for this indication. The only option for treating this sort of issue before had been surgery. The approval was based on a phase III study where 42% of patients taking the drug, also called everolimus, responded to the treatment, while 0% of the placebo group responded.
The ruling will allow Novartis to market the drug in the 27 member countries of the EU, as well as Iceland and Norway. Specifically, the drug has been approved in its tablet form, and is to be used for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex, or TSC, who don't need immediate surgery.
Votubia also has EU approval to treat a non-cancerous brain tumor associated with TSC.
The article Novartis Cancer Drug Gets Another EU OK originally appeared on Fool.com.
John Divine has no positions in the stocks mentioned above. You can follow him on Twitter @divinebizkid and on Motley Fool CAPS @TMFDivine.The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.